Plano, Texas — According to state and local economic development sources Reata Pharmaceuticals plans to invest $34,800,000.00 to build out 230,202 square feet of new space in Plano. The company plans to occupy the new space at 6100 Legacy Drive Floors 01, 11-12, 17-22 in Plano, on or about July 1, 2022. According to the company website At Reata Pharmaceuticals, we develop small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases with no approved or effective therapy. Our focus is to apply our deep understanding of the cellular response to injury to develop innovative medicines that create a better tomorrow for patients with life-threatening diseases. Our Nrf2 activators, bardoxolone methyl and omaveloxolone, take advantage of new insights into how genes involved in cellular metabolism and mitochondrial function play a primary role in switching the cellular inflammatory response on and off. We believe these compounds show promise as potential treatments across a range of diseases that have few or no treatment options. Beyond our current technologies, we actively pursue scientific discoveries to advance medicine. Our robust preclinical development program is focused on several therapeutic areas that lack treatment options. We value strategic opportunities that arise through partnerships with premier academic institutions and research companies.

To learn more about Reata Pharmaceuticals, visit http://www.reatapharma.com/

Company Contact:
Warren Huff, Chief Executive Officer
warren.huff@reatapharma.com
https://www.linkedin.com/in/warren-huff-2b38442/
972-573-0570

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved